Ciclosporin population pharmacokinetics and bayesian estimation in thoracic transplant recipients

Clinical Pharmacokinetics

Volumn 52, Issue 4, 2013, Pages 277-288

  Fruit, Dorothée ^a,b,c   Rousseau, Annick ^a,b   Amrein, Catherine ^d   Rollé, Florence ^c   Kamar, Nassim ^e,f,g   Sebbag, Laurent ^h   Redonnet, Michel ⁱ   Epailly, Eric ^j   Marquet, Pierre ^a,b,c   Prémaud, Aurélie ^a,b  

^a INSERM   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE TOULOUSE   (France)

^g CHU PURPAN   (France)

^h LOUIS PRADEL HOSPITAL   (France)

ⁱ HÔPITAL CHARLES NICOLLE   (France)

^j HÔPITAL CIVIL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADULT; AGED; ALLOGRAFT; ARTICLE; BAYES THEOREM; CARDIAC GRAFT REJECTION; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPARTMENT MODEL; CONTROLLED STUDY; CYSTIC FIBROSIS; DEMOGRAPHY; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEREDITY; HUMAN; HUMAN TISSUE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMA CONCENTRATION-TIME CURVE; POPULATION DYNAMICS; PRIORITY JOURNAL; THORAX SURGERY;

ADULT; AGED; AREA UNDER CURVE; BAYES THEOREM; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; SEX FACTORS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84877052008     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0037-x     Document Type: Article

References (40)

1. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs. 2001;61(13):1957-2016.
2. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet. 2009;48(7):419-62.
3. Keown P, Kahan BD, Johnston A, et al. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). Transplant Proc. 1998;30(5):1645-9.
4. Kahan BD, Welsh M, Rutzky LP. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit. 1995;17(6):621-4.
5. Balram C, Sivathasan C, Cheung YB, et al. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients. J Heart Lung Transplant. 2002;21(9):1016-21.
6. David OJ, Johnston A, Cooney GF. Sparse sample measurement of cyclosporin AUC after Neoral in heart transplant patients. Ther Drug Monit. 1999;21(4):447.
7. Hangler HB, Ruttmann E, Geltner C, et al. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation. Clin Transplant. 2008;22(1):35-40.
8. Dumont RJ, Partovi N, Levy RD, et al. A limited sampling strategy for cyclosporine area under the curve monitoring in lung transplant recipients. J Heart Lung Transplant. 2001;20(8):897-900.
9. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol. 2003;58(12):813-20.
10. Solari SG, Goldberg LR, DeNofrio D, et al. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. Ther Drug Monit. 2005;27(4):417-21.
11. Ray JE, Keogh AM, McLachlan AJ. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring. J Heart Lung Transplant. 2006;25(10):1223-9.
12. Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit. 2003;25(1):28-35.
13. Ray JE, Keogh AM, McLachlan AJ, et al. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant. 2003;22(7):715-22.
14. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49(3):141-75.
15. Ji E, Kim MY, Yun HY, et al. Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. Pharmacotherapy. 2011;31(6):574-84.
16. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet. 2006;45(9):905-22.
17. Falck P, Midtvedt K, Van Le TT, et al. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. Clin Pharmacokinet. 2009;48(9):615-23.
18. Chen B, Zhang W, Gu Z, et al. Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2011;67(6):601-12.
19. Hesselink DA, van GT, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76(6):545-56.
20. Sun B, Li XY, Gao JW, et al. Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. Ther Drug Monit. 2010;32(6):715-22.
21. Bourgoin H, Paintaud G, Buchler M, et al. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. Br J Clin Pharmacol. 2005;59(1):18-27.
22. Yin OQ, Lau SK, Chow MS. Population pharmacokinetics of cyclosporine in Chinese cardiac transplant recipients. Pharmacotherapy. 2006;26(6):790-7.
23. Parke J, Charles BG. Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol. 2000;56(6-7):481-7.
24. Rosenbaum SE, Baheti G, Trull AK, et al. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit. 2005;27(2):116-22.
25. Sauvage FL, Gaulier JM, Lachatre G, et al. A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. Ther Drug Monit. 2006;28(1):123-30.
26. Picard N, Djebli N, Sauvage FL, et al. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos. 2007;35(3):350-5.
27. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73(5):1162-9.
28. Rousseau A, Leger F, Le MY, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit. 2004;26(1):23-30.
29. Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer. 1998;34(1):92-7.
30. Urien S. Rfn, R for Nonmem: a graphical interface for Nonmem outputs [abstract no. 1424]. PAGE17 (2008). http://www.page-meeting.org/?abstract=1424. Accessed 24 Jan 2013.
31. R development Core Team. R: a language environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009.
32. D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 1997.
33. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503-12.
34. Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and Bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit. 2007;29(1):96-102.
35. Min DI, Lee M, Ku YM, et al. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther. 2000;68(5):478-86.
36. Lampen A, Christians U, Bader A, et al. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology. 1996;52(3):159-68.
37. Tan KK, Trull AK, Uttridge JA, et al. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur J Clin Pharmacol. 1995;48(3-4):285-9.
38. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003;13(2):89-95.
39. Mai I, Stormer E, Goldammer M, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol. 2003;43(10):1101-7.
40. Bouamar R, Hesselink DA, van Schaik RH, et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit. 2011;33(2):178-84.